A randomized, placebo controlled, phase Ib trial to evaluate the safety and pharmacokinetics of NOV-205 [Novelos Therapeutics] in chronic viral hepatitis C subjects (genotype 1) who have failed treatment with pegylated interferon [peginterferon] plus ribavirin
Phase of Trial: Phase I
Latest Information Update: 11 Feb 2014
At a glance
- Drugs Glutathione/inosine (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Cellectar Biosciences
- 11 Feb 2014 Novelos Therapeutics now known as Cellectar Biosciences
- 14 Dec 2007 Status changed from recruiting to completed according to a Novelos Therapeutics media release.
- 02 Oct 2006 New trial record.